<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850603</url>
  </required_header>
  <id_info>
    <org_study_id>MPT01</org_study_id>
    <nct_id>NCT00850603</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®</brief_title>
  <official_title>Safety and Immunogenicity of Intradermal, and Low-dose Subcutaneous vs Subcutaneous Administration of Menomune® - A/C/Y/W-135</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to study the administration of the Menomune vaccine given
      intradermally and low-dose subcutaneously versus standard subcutaneously. This study will
      describe the immunogenicity of Menomune® - A/C/Y/W-135 administered subcutaneously (standard
      dose) versus intradermally over a dose range (1/10th, 2/10th, and 3/10th of standard dose)
      and a low dose (2/10th of standard dose) subcutaneously.

      The secondary objective is to describe the safety of the subcutaneous (SC) and intradermal
      (ID) routes at different dosages
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will provide a proof of concept that a dose range of Menomune given ID can induce
      an immune response that is comparable to standard dosing by the SC route, and is equivalent
      or superior to a low dose given SC.

      Subjects will be randomized according to a computer-generated randomization schedule to
      receive the vaccine by SC injection or by ID injection at different dosages.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With ≥ 4-Fold Rise in Antibody Titers</measure>
    <time_frame>Baseline to 28 days post vaccination</time_frame>
    <description>Percentage of participants with a 4-fold rise in Serum bactericidal assay using baby rabbit complement (SBA-BR) antibody titers to each meningococcal serogroup from baseline to Day 28 post-vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Each Meningococcal Serogroup at Baseline and 28 Days Post-vaccination.</measure>
    <time_frame>Baseline (Day 0) and Day 28 post-vaccination</time_frame>
    <description>GMTs and their 95% confidence interval to the vaccine meningococcal serogroups at Day 0 and Day 28 post-vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Intensity of Solicited Local and Systemic Reactions Post-vaccination.</measure>
    <time_frame>Day 0 to 7 days post-vaccination</time_frame>
    <description>Participants with solicited local and systemic reactions and intensity within 7 days following vaccination with Menomune®</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Meningococcal Infections</condition>
  <condition>Meningitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mL Subcutaneous arm (Menomune® )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mL Subcutaneous arm (Menomune®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.05 mL Intradermal arm (Menomune®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mL Intradermal arm (Menomune®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.15 mL Intradermal arm (Menomune®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Menomune® - A/C/Y/W-135</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined</intervention_name>
    <description>0.1 mL, Subcutaneous</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Menomune® - A/C/Y/W-135</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined</intervention_name>
    <description>0.05 mL, Intradermal</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Menomune® - A/C/Y/W-135</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined</intervention_name>
    <description>0.1 mL, Intradermal</description>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Menomune® - A/C/Y/W-135</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined</intervention_name>
    <description>0.15 mL, Intradermal</description>
    <arm_group_label>Group 5</arm_group_label>
    <other_name>Menomune® - A/C/Y/W-135</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  18 to 55 years of age.

          -  Willing to return for 3 follow-up visits and comply with a 30 day follow-up period.

          -  Signed an informed consent form.

        Exclusion Criteria :

          -  Allergy to any component of the vaccine and latex.

          -  Known or suspected immunodeficiency or receipt of immunosuppressive therapy or blood
             products within the previous two months.

          -  History of serious chronic diseases (such as cardiac or renal disease).

          -  Acute febrile illness at the time of visit.

          -  Pregnancy.

          -  Receipt of any vaccine within the 28 days prior to enrollment.

          -  Receipt of meningococcal vaccine (example in Military) within the past 5 years or
             history of meningococcal disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>East Stroudsburg</city>
        <state>Pennsylvania</state>
        <zip>18301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2009</study_first_submitted>
  <study_first_submitted_qc>February 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2009</study_first_posted>
  <results_first_submitted>March 13, 2009</results_first_submitted>
  <results_first_submitted_qc>March 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2009</results_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menomune® - A/C/Y/W-135</keyword>
  <keyword>Meningococcal Infections</keyword>
  <keyword>Meningitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled from 15 through 16 October 2002 in 1 US site</recruitment_details>
      <pre_assignment_details>A total of 170 participants that met the inclusion and exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.5 mL Subcutaneous Menomune®</title>
          <description>Participants received 0.5 mL Subcutaneous Menomune®</description>
        </group>
        <group group_id="P2">
          <title>0.1 mL Subcutaneous Menomune®</title>
          <description>Participants received 0.1 mL Subcutaneous Menomune®</description>
        </group>
        <group group_id="P3">
          <title>0.05 mL Intradermal Menomune®</title>
          <description>Participants received 0.05 mL Intradermal Menomune®</description>
        </group>
        <group group_id="P4">
          <title>0.1 mL Intradermal Menomune®</title>
          <description>Participants received 0.1 mL Intradermal Menomune®</description>
        </group>
        <group group_id="P5">
          <title>0.15 mL Intradermal Menomune®</title>
          <description>Participants received 0.15 mL Intradermal Menomune®</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.5 mL Subcutaneous Menomune®</title>
          <description>Participants received 0.5 mL Subcutaneous Menomune®</description>
        </group>
        <group group_id="B2">
          <title>0.1 mL Subcutaneous Menomune®</title>
          <description>Participants received 0.1 mL Subcutaneous Menomune®</description>
        </group>
        <group group_id="B3">
          <title>0.05 mL Intradermal Menomune®</title>
          <description>Participants received 0.05 mL Intradermal Menomune®</description>
        </group>
        <group group_id="B4">
          <title>0.1 mL Intradermal Menomune®</title>
          <description>Participants received 0.1 mL Intradermal Menomune®</description>
        </group>
        <group group_id="B5">
          <title>0.15 mL Intradermal Menomune®</title>
          <description>Participants received 0.15 mL Intradermal Menomune®</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="34"/>
            <count group_id="B4" value="34"/>
            <count group_id="B5" value="34"/>
            <count group_id="B6" value="170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.8" spread="9.68"/>
                    <measurement group_id="B2" value="24.3" spread="7.10"/>
                    <measurement group_id="B3" value="24.4" spread="7.64"/>
                    <measurement group_id="B4" value="24.5" spread="8.46"/>
                    <measurement group_id="B5" value="28.9" spread="12.85"/>
                    <measurement group_id="B6" value="25.6" spread="9.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With ≥ 4-Fold Rise in Antibody Titers</title>
        <description>Percentage of participants with a 4-fold rise in Serum bactericidal assay using baby rabbit complement (SBA-BR) antibody titers to each meningococcal serogroup from baseline to Day 28 post-vaccination.</description>
        <time_frame>Baseline to 28 days post vaccination</time_frame>
        <population>4-Fold rise analysis was in the per-protocol population with valid serology data</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mL Subcutaneous Menomune®</title>
            <description>Participants received 0.5 mL Subcutaneous Menomune®</description>
          </group>
          <group group_id="O2">
            <title>0.1 mL Subcutaneous Menomune®</title>
            <description>Participants received 0.1 mL Subcutaneous Menomune®</description>
          </group>
          <group group_id="O3">
            <title>0.05 mL Intradermal Menomune®</title>
            <description>Participants received 0.05 mL Intradermal Menomune®</description>
          </group>
          <group group_id="O4">
            <title>0.1 mL Intradermal Menomune®</title>
            <description>Participants received 0.1 mL Intradermal Menomune®</description>
          </group>
          <group group_id="O5">
            <title>0.15 mL Intradermal Menomune®</title>
            <description>Participants received 0.15 mL Intradermal Menomune®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥ 4-Fold Rise in Antibody Titers</title>
          <description>Percentage of participants with a 4-fold rise in Serum bactericidal assay using baby rabbit complement (SBA-BR) antibody titers to each meningococcal serogroup from baseline to Day 28 post-vaccination.</description>
          <population>4-Fold rise analysis was in the per-protocol population with valid serology data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningococcal serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Intensity of Solicited Local and Systemic Reactions Post-vaccination.</title>
        <description>Participants with solicited local and systemic reactions and intensity within 7 days following vaccination with Menomune®</description>
        <time_frame>Day 0 to 7 days post-vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.5 mL Subcutaneous Menomune®</title>
            <description>Participants received 0.5 mL Subcutaneous Menomune®</description>
          </group>
          <group group_id="O2">
            <title>0.1 mL Subcutaneous Menomune®</title>
            <description>Participants received 0.1 mL Subcutaneous Menomune®</description>
          </group>
          <group group_id="O3">
            <title>0.05 mL Intradermal Menomune®</title>
            <description>Participants received 0.05 mL Intradermal Menomune®</description>
          </group>
          <group group_id="O4">
            <title>0.1 mL Intradermal Menomune®</title>
            <description>Participants received 0.1 mL Intradermal Menomune®</description>
          </group>
          <group group_id="O5">
            <title>0.15 mL Intradermal Menomune®</title>
            <description>Participants received 0.15 mL Intradermal Menomune®</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Intensity of Solicited Local and Systemic Reactions Post-vaccination.</title>
          <description>Participants with solicited local and systemic reactions and intensity within 7 days following vaccination with Menomune®</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 3 Local Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness ( ≥ 2 inchs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling ( ≥ 2 inchs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Tenderness (disabling)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (disabling)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 3 Systemic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (≥ 39.6 ºC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Chills (disabling)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (disabling)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Dizziness (disabling)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (disabling)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (disabling)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Nausea (disabling)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (≥3 episodes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Diarrhea (≥3 episodes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia (disabling)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Each Meningococcal Serogroup at Baseline and 28 Days Post-vaccination.</title>
        <description>GMTs and their 95% confidence interval to the vaccine meningococcal serogroups at Day 0 and Day 28 post-vaccination.</description>
        <time_frame>Baseline (Day 0) and Day 28 post-vaccination</time_frame>
        <population>Geometric mean titers were determined in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mL Subcutaneous Menomune®</title>
            <description>Participants received 0.5 mL Subcutaneous Menomune®</description>
          </group>
          <group group_id="O2">
            <title>0.1 mL Subcutaneous Menomune®</title>
            <description>Participants received 0.1 mL Subcutaneous Menomune®</description>
          </group>
          <group group_id="O3">
            <title>0.05 mL Intradermal Menomune®</title>
            <description>Participants received 0.05 mL Intradermal Menomune®</description>
          </group>
          <group group_id="O4">
            <title>0.1 mL Intradermal Menomune®</title>
            <description>Participants received 0.1 mL Intradermal Menomune®</description>
          </group>
          <group group_id="O5">
            <title>0.15 mL Intradermal Menomune®</title>
            <description>Participants received 0.15 mL Intradermal Menomune®</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Each Meningococcal Serogroup at Baseline and 28 Days Post-vaccination.</title>
          <description>GMTs and their 95% confidence interval to the vaccine meningococcal serogroups at Day 0 and Day 28 post-vaccination.</description>
          <population>Geometric mean titers were determined in the per-protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningococcal serogroup A (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462.4" lower_limit="222.4" upper_limit="961.4"/>
                    <measurement group_id="O2" value="320.4" lower_limit="127.7" upper_limit="803.8"/>
                    <measurement group_id="O3" value="267.0" lower_limit="114.5" upper_limit="622.7"/>
                    <measurement group_id="O4" value="381.6" lower_limit="195.7" upper_limit="743.8"/>
                    <measurement group_id="O5" value="261.6" lower_limit="131.1" upper_limit="522.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal serogroup A (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5496.3" lower_limit="3262.8" upper_limit="9258.7"/>
                    <measurement group_id="O2" value="3662.7" lower_limit="2392.4" upper_limit="5607.7"/>
                    <measurement group_id="O3" value="1775.6" lower_limit="1116.3" upper_limit="2824.5"/>
                    <measurement group_id="O4" value="3079.0" lower_limit="2298.4" upper_limit="4124.7"/>
                    <measurement group_id="O5" value="4013.3" lower_limit="2575.7" upper_limit="6253.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal serogroup C (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1" lower_limit="20.1" upper_limit="115.0"/>
                    <measurement group_id="O2" value="85.1" lower_limit="34.6" upper_limit="209.7"/>
                    <measurement group_id="O3" value="50.8" lower_limit="20.7" upper_limit="124.4"/>
                    <measurement group_id="O4" value="53.0" lower_limit="21.6" upper_limit="129.7"/>
                    <measurement group_id="O5" value="41.5" lower_limit="18.8" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal serogroup C (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2989.0" lower_limit="1475.1" upper_limit="6056.5"/>
                    <measurement group_id="O2" value="1751.3" lower_limit="934.0" upper_limit="3283.8"/>
                    <measurement group_id="O3" value="1478.0" lower_limit="647.4" upper_limit="3374.3"/>
                    <measurement group_id="O4" value="1307.8" lower_limit="661.8" upper_limit="2584.4"/>
                    <measurement group_id="O5" value="2780.6" lower_limit="1428.3" upper_limit="5413.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal serogroup Y (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.3" lower_limit="138.3" upper_limit="656.5"/>
                    <measurement group_id="O2" value="166.8" lower_limit="73.0" upper_limit="381.5"/>
                    <measurement group_id="O3" value="164.7" lower_limit="73.3" upper_limit="370.2"/>
                    <measurement group_id="O4" value="216.4" lower_limit="103.8" upper_limit="451.2"/>
                    <measurement group_id="O5" value="189.0" lower_limit="93.5" upper_limit="382.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal serogroup Y (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1883.0" lower_limit="1185.2" upper_limit="2991.4"/>
                    <measurement group_id="O2" value="2002.7" lower_limit="1163.3" upper_limit="3447.9"/>
                    <measurement group_id="O3" value="1390.3" lower_limit="742.1" upper_limit="2604.8"/>
                    <measurement group_id="O4" value="1603.6" lower_limit="1111.6" upper_limit="2313.3"/>
                    <measurement group_id="O5" value="1887.6" lower_limit="1120.4" upper_limit="3180.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal serogroup W-135 (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" lower_limit="15.3" upper_limit="69.8"/>
                    <measurement group_id="O2" value="37.7" lower_limit="19.0" upper_limit="74.7"/>
                    <measurement group_id="O3" value="47.7" lower_limit="24.5" upper_limit="93.0"/>
                    <measurement group_id="O4" value="34.1" lower_limit="16.0" upper_limit="72.8"/>
                    <measurement group_id="O5" value="19.4" lower_limit="9.7" upper_limit="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal serogroup W-135 (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1374.1" lower_limit="846.9" upper_limit="2229.4"/>
                    <measurement group_id="O2" value="856.3" lower_limit="465.9" upper_limit="1573.8"/>
                    <measurement group_id="O3" value="1390.3" lower_limit="805.1" upper_limit="2400.9"/>
                    <measurement group_id="O4" value="1307.8" lower_limit="881.6" upper_limit="1940.2"/>
                    <measurement group_id="O5" value="2006.7" lower_limit="1204.5" upper_limit="3343.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination for 28 days post-vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.5 mL Subcutaneous Menomune®</title>
          <description>Participants received 0.5 mL Subcutaneous Menomune®</description>
        </group>
        <group group_id="E2">
          <title>0.1 mL Subcutaneous Menomune®</title>
          <description>Participants received 0.1 mL Subcutaneous Menomune®</description>
        </group>
        <group group_id="E3">
          <title>0.05 mL Intradermal Menomune®</title>
          <description>Participants received 0.05 mL Intradermal Menomune®</description>
        </group>
        <group group_id="E4">
          <title>0.1 mL Intradermal Menomune®</title>
          <description>Participants received 0.1 mL Intradermal Menomune®</description>
        </group>
        <group group_id="E5">
          <title>0.15 mL Intradermal Menomune®</title>
          <description>Participants received 0.15 mL Intradermal Menomune®</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site redness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E5" events="18" subjects_affected="18" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Injection site tenderness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

